Study guide

2.3 Utility Requirements & USPTO Utility Guidelines

USPTO Registration Examination Patent Bar

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Overview, Registration & MPEP Structure

1.1 Patent Bar Exam Format & Administration 1.2 Practitioner Qualifications & Eligibility 1.3 MPEP Structure & Effective Search Strategies

2 Chapter 2: Subject Matter Eligibility & Utility (35 U.S.C. § 101)

2.1 Patent-Eligible Subject Matter & Statutory Categories 2.2 Judicial Exceptions & the Alice/Mayo Framework 2.3 Utility Requirements & USPTO Utility Guidelines

3 Chapter 3: Novelty & Prior Art Under the AIA (35 U.S.C. § 102)

3.1 First-Inventor-to-File (FITF) & Effective Filing Dates 3.2 The One-Year Inventor Grace Period & Exceptions 3.3 Prior Art Types & Public Availability Standards

4 Chapter 4: Nonobviousness Analysis (35 U.S.C. § 103)

4.1 The Graham Factors & KSR Obviousness Framework 4.2 Combining Prior Art References & Motivation to Combine 4.3 Overcoming § 103 Rejections & Rule 132 Affidavits

5 Chapter 5: Specification & Disclosure Requirements (35 U.S.C. § 112(a))

5.1 Written Description Requirement 5.2 Enablement Requirement & Wands Factors 5.3 Best Mode Requirement & Current Post-AIA Status

6 Chapter 6: Claim Requirements & Definiteness (35 U.S.C. § 112(b)-(f))

6.1 Definiteness & Claim Precision 6.2 Independent & Dependent Claim Construction 6.3 Special Claim Formats: Means-Plus-Function & Markush Claims

7 Chapter 7: Application Types & Filing Procedures (MPEP Chapter 600)

7.1 Provisional Patent Applications 7.2 Nonprovisional Application Parts & Formalities 7.3 Inventor Oaths, Declarations & Assignments

8 Chapter 8: Duty of Disclosure & Information Disclosure Statements

8.1 Duty of Candor & Good Faith 8.2 Information Disclosure Statements (IDS) Requirements 8.3 Correcting Non-Disclosure & Duty Compliance

9 Chapter 9: Patent Prosecution & Office Action Responses (MPEP Chapter 700)

9.1 Initial Examination & Non-Final Office Actions 9.2 Statutory Deadlines & Extension of Time 9.3 Final Office Actions & Post-Final Practice

10 Chapter 10: Continuing Applications & Copendency

10.1 Continuation Applications 10.2 Divisional Applications 10.3 Continuation-in-Part (CIP) Applications & Priority Allocation

11 Chapter 11: Appeals & Interferences/Derivation (MPEP Chapter 1200 & 2300)

11.1 Ex Parte Appeals to the PTAB 11.2 PTAB Appeal Decisions & Judicial Review 11.3 Derivation Proceedings Under the AIA

12 Chapter 12: Post-Grant Proceedings & Corrections (MPEP Chapters 1400 & 2200)

12.1 Reissue Applications & Certificates of Correction 12.2 Ex Parte Reexamination & Supplemental Examination 12.3 Inter Partes Review (IPR) & Post-Grant Review (PGR)

13 Chapter 13: Patent Term, Maintenance Fees & Ownership

13.1 Patent Term Calculation & Patent Term Adjustment (PTA) 13.2 Maintenance Fees & Expiration 13.3 Inventorship, Ownership & Assignment Recordation 13.4 Patent Term Extension Under 35 U.S.C. § 156

14 Chapter 14: International Patent Practice & PCT (MPEP Chapter 1800)

14.1 The Patent Cooperation Treaty (PCT) Overview 14.2 PCT International Phase & Chapter I / Chapter II 14.3 National Phase Entry Under 35 U.S.C. § 371

15 Chapter 15: Special Patent Categories & Professional Conduct

15.1 Design Patents & Plant Patents 15.2 USPTO Rules of Professional Conduct 15.3 Patent Bar Exam Strategy & Open-Book Navigation Tips

16 Chapter 16: Security, Access, Representation & Filing Mechanics

16.1 Secrecy, Application Access & Foreign Filing Licenses 16.2 Representation, Power of Attorney & Correspondence 16.3 Filing Receipt, Certificates of Transmission & Signatures

17 Chapter 17: Restriction, Publication, Allowance & Office Authority

17.1 Restriction, Election, Rejoinder & Double Patenting 17.2 Publication, Preissuance Submissions & Protests 17.3 Allowance, Issue Fee & Withdrawal from Issue 17.4 Examiner Interviews, Petitions & Office Authority

18 Chapter 18: Biotechnology Disclosure & Patent Prosecution Highway

18.1 Biological Deposits & Sequence Listings 18.2 Global/IP5 Patent Prosecution Highway

19 Chapter 19: AIA Trial Practice Under the Consolidated Guide

19.1 AIA Trial Petitions, Preliminary Response & Institution 19.2 AIA Trial Discovery, Motions, Hearing & Final Decision

2.3 Utility Requirements & USPTO Utility Guidelines

Key Takeaways Explain This Topic AI

35 U.S.C. § 101 requires an invention to be 'useful,' establishing the threshold requirement of patent utility.

Under the USPTO Utility Examination Guidelines (MPEP § 2107), an applicant must satisfy three utility criteria: Specific Utility, Substantial Utility, and Credible Utility.

Substantial utility requires real-world, immediate utility in present form; under Brenner v. Manson, a patent is not a hunting license or a reward for research.

Under In re Fisher, Expressed Sequence Tags (ESTs) used merely as generic gene probes lack specific and substantial utility when the underlying gene function is unknown.

Claims violating fundamental physical laws (e.g., perpetual motion machines) are rejected under § 101 for lack of utility coupled with § 112(a) for lack of enablement.

Last updated: August 2026

2.3 Utility Requirements & USPTO Utility Guidelines

In addition to fitting within a statutory category under 35 U.S.C. § 101, an invention must be "useful." The utility requirement derives from Article I, Section 8, Clause 8 of the U.S. Constitution, which authorizes Congress to promote the progress of the "useful Arts."

The USPTO Utility Examination Guidelines (MPEP § 2107)

To enforce the utility threshold consistently, the USPTO established the Utility Examination Guidelines (MPEP § 2107). An application meets the § 101 utility requirement if it discloses a well-established utility OR asserts a utility that satisfies three cumulative criteria:

Specific Utility: The utility must be specific to the claimed subject matter, rather than a generic utility that could apply broadly to an entire class of chemical compounds or biological molecules.

Substantial Utility: The invention must have a real-world, immediate utility in its present form without requiring further research or development to identify a practical use.

Credible Utility: The asserted utility must be believable to a Person Having Ordinary Skill in the Art (POSITA) in light of the specification disclosure and state of the art.

Utility Criterion Examination Requirement (MPEP § 2107) Example of Non-Compliance

Specific Utility Particular utility defined for the specific entity claimed. Claiming a novel protein acts as a 'biological marker' without identifying what specific condition or disease it marks.

Substantial Utility Immediate, practical, real-world usefulness in current state ( Brenner v. Manson ). Claiming a novel steroid compound as an intermediate for further scientific research to see if it exhibits anti-tumor activity.

Credible Utility Believable to a POSITA based on science and logic. Claiming a anti-gravity device or perpetual motion machine operating at 150% efficiency.

  • Landmark Precedents: Brenner v. Manson & In re Fisher
  • The Brenner v. Manson Standard

In Brenner v. Manson , 383 U.S. 519 (1966), the Supreme Court established the foundational standard for substantial utility. The applicant claimed a process for producing a novel steroid compound, admitting that the compound's therapeutic efficacy was unknown and under investigation.

The Supreme Court rejected the claim, establishing the famous rule:

"A patent is not a hunting license. It is not a reward for the search, but but for its successful completion."

A chemical compound or process is not useful under § 101 merely because it is the object of scientific research.

Gene Sequences & ESTs: In re Fisher

In In re Fisher , 421 F.3d 1365 (Fed. Cir. 2005), the Federal Circuit applied Brenner v. Manson to biotechnology claims involving Expressed Sequence Tags (ESTs) :

The applicant claimed five ESTs (short cDNA sequences) useful for detecting nucleic acid expression in maize.

Because the applicant did not know the structure, function, or identity of the underlying genes expressed by the ESTs, the court held that using ESTs merely as generic gene probes or chromosome markers was a "throwaway utility."

ESTs lacking known underlying gene functions fail both specific and substantial utility requirements under § 101.

  • Throwaway vs. Well-Known Utilities
  • Throwaway Utilities (Insufficient)

Utilities that can be asserted for virtually any physical object fail the substantial utility test. Examples of throwaway utilities that do NOT satisfy § 101:

Using a novel chemical compound as a paperweight, landfill material, or ship ballast.

Using an uncharacterized DNA sequence as a generic molecular weight marker.

Using a complex mechanical device as a doorstop.

Well-Known Utilities (Sufficient Without Explicit Assertion)

If a utility for an invention is well-established —meaning a POSITA would immediately appreciate the utility without needing it spelled out—the applicant does not need to explicitly state the utility in the specification (MPEP § 2107.01).

Example: Claiming a hand-held tool comprising a heavy iron head and wooden handle (a hammer) has a well-known utility for driving nails.

Pharmaceutical Claims & In Vitro / In Vivo Evidentiary Standards

A critical Patent Bar exam topic is how examiners evaluate utility for pharmaceutical and therapeutic claims :

Clinical Human Trials NOT Required: The USPTO does not require human clinical trial data (FDA Phase I/II/III results) to establish credible utility under § 101.

In Vitro & Animal Model Data Are Sufficient: Pharmacological activity demonstrated through in vitro tissue assays or in vivo animal model testing is fully sufficient to establish credible utility for therapeutic claims, unless extraordinary evidence contradicts the findings (MPEP § 2107.02).

Safety & Efficacy vs. Patent Utility: FDA approval requires proof of safety and commercial efficacy. In contrast, Patent Office utility requires only a credible assertion of specific and substantial practical usefulness.

Perpetual Motion Machines & Inoperability Rejection Procedures

When a patent application claims an invention that violates fundamental natural laws—such as a perpetual motion machine or a device violating the First or Second Law of Thermodynamics—the examiner applies a specific rejection protocol (MPEP § 2107.01):

Examiner Dual Rejection Protocol

Rejection under 35 U.S.C. § 101: Rejected for lack of credible utility because the invention is physically inoperable.

Rejection under 35 U.S.C. § 112(a): Rejected for lack of enablement because an inoperable invention cannot be described in a manner that enables a POSITA to make and use it.

Rebutting the Rejection (37 C.F.R. § 1.91)

To overcome a perpetual motion or inoperability rejection, the applicant cannot rely solely on argument or theoretical assertions. Under 37 C.F.R. § 1.91 , the USPTO Director or Examiner may require the applicant to submit a working model or physical demonstration proving operability.

Loading diagram... USPTO Utility Examination Guidelines Workflow (MPEP 2107)